Kaye I. Foster-Cheek
CIK: 0001312622
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 5, 2026PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
75K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
9K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
13.5K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
13.5K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
9K shares- - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 4, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
55K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 5, 2026 |  PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 75,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 9,006 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 13,510 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 13,510 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 9,006 | - | - | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,816 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 4, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 55,000 | - | - | Direct |
1-16 of 16 transactions
About Foster-Cheek Kaye I
Foster-Cheek Kaye I (SEC CIK 0001312622) files insider reports with the SEC as Director of AGIOS PHARMACEUTICALS, INC. (AGIO) and Director of Prime Medicine, Inc. (PRME).
Signal8 holds 5 ownership filings by Foster-Cheek Kaye I, all Form 4s, filed between Jun 5, 2025 and Jun 23, 2026. Those filings report 16 transactions, from Jun 4, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Foster-Cheek Kaye I's filings is in CAMBRIDGE, MA.
Recent filings by Foster-Cheek Kaye I
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 18, 2026: Grants or awards of AGIO derivative securities (2 lines, Form 4, code A).
- Jun 5, 2026: Grant or award of PRME derivative securities (Form 4, code A).
- Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
- Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Gheuens Sarah, Chief Medical Officer
- Backstrom Jay T., Director
- Ballal Rahul D., Director
- CAPELLO JEFFREY D, Director
- FOUSE JACQUALYN A, Director
- Ho Maykin, Director